SCHEMBL2469445

SCHEMBL2469445

CCN(O)S(=O)(=O)C(NC(=O)c1ccccc1OC)C1(c2ccccc2)CCCNCC1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
ALDH1A1 P00352 2/20 0.43
SLC6A9 P48067 1/20 0.42
KCNA3 P22001 9/20 0.40
HPGD P15428 1/20 0.39
KDM4E B2RXH2 1/20 0.37
CHRM3 P20309 1/20 0.37
ITGB1 P05556 2/20 0.36
ITGA4 P13612 2/20 0.36
ITGB7 P26010 2/20 0.36
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
HCN1 O60741 1/20 0.36
HCN4 Q9Y3Q4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2469459 0.96 SLC6A9 (0.44) MEN1KMT2AALDH1A1SLC6A9KCNA3
SCHEMBL2497213 0.91 MEN1 (0.42) MEN1KMT2AALDH1A1SLC6A9KCNA3
SCHEMBL2468321 0.90 ALDH1A1 (0.44) MEN1KMT2AALDH1A1SLC6A9KCNA3
SCHEMBL2469896 0.90 SLC6A9 (0.43) MEN1KMT2AALDH1A1SLC6A9KCNA3
SCHEMBL2469428 0.87 ALDH1A1 (0.44) MEN1KMT2AALDH1A1SLC6A9KCNA3
SCHEMBL2468331 0.87 ALDH1A1 (0.44) MEN1KMT2AALDH1A1SLC6A9KCNA3
SCHEMBL2468186 0.87 ALDH1A1 (0.42) MEN1KMT2AALDH1A1SLC6A9KCNA3
SCHEMBL2473080 0.87 ALDH1A1 (0.42) MEN1KMT2AALDH1A1SLC6A9KCNA3
SCHEMBL2472012 0.87 ALDH1A1 (0.42) MEN1KMT2AALDH1A1SLC6A9KCNA3
SCHEMBL2471728 0.87 ALDH1A1 (0.42) MEN1KMT2AALDH1A1SLC6A9KCNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP disclosed
EP-1501467-B1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL MYERS SQUIBB CO (US) 2012-05-09 EP disclosed
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7005436-B2 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB COMPANY (US) 2006-02-28 US disclosed
US-20060014792-A1 Heterocyclo inhibitors of potassium channel function LLOYD JOHN 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014792-A1 Heterocyclo inhibitors of potassium channel function KCNJ2, KCNH2, KCNQ5 MEN1 3501/4885KMT2A 957/4885ALDH1A1 3941/4885
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 MEN1 3501/4885KMT2A 957/4885ALDH1A1 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.